English
  • Ruxolitinib

    Ruxolitinib

    API lub npe Qhov taw qhia Innovator Patent Expiry Date (Tebchaws Asmeskas)
    Ruxolitinib Myelofibrosis Novartis Lub Xya Hli 6, 2024
    kev nugnthuav dav
  • Relugolix

    Relugolix

    API lub npe Qhov taw qhia Innovator Patent Expiry Date (Tebchaws Asmeskas)
    Relugolix Prostatic mob qog noj ntshav Takeda thiab ASKA Peb Hlis 24, 2024
    kev nugnthuav dav
  • Rimegepant

    Rimeegept

    API lub npe Qhov taw qhia Innovator Patent Expiry Date (Tebchaws Asmeskas)
    Rimeegept Migraine mob taub hau Biohaven Lub Ob Hlis 22, 2031

     

    kev nugnthuav dav
  • Relugolix 737789-87-6

    Relugolix 737789-87-6

    API lub npe Qhov taw qhia Specification US DMF EU DMF CEP
    Ribociclib CAS Nr .: 737789-87-6 Antineoplastic Hauv tsev      
    kev nugnthuav dav
  • Ribociclib 1374639-75-4

    Ribociclib 1374639-75-4

    API lub npe Qhov taw qhia Innovator Patent Expiry Date (Tebchaws Asmeskas)
    Ribociclib 1374639-75-4 HR-positive, HER2-negative Andvance ormetastaticbreast Cancers Novartis
    Pharmaceuticals    		 Peb Hlis 27, 2028
    kev nugnthuav dav
  • Rivaroxaban

    Rivaroxaban

    API lub npe Qhov taw qhia Specification US DMF EU DMF CEP
    Rivaroxaban Anticoagulant Hauv tsev TDP    
    kev nugnthuav dav
  • Rosuvastatin Calcium

    Rosuvastatin Calcium

    API lub npe Qhov taw qhia Specification US DMF EU DMF CEP
    Rosuvastatin Calcium Hypercholesterolemia Hauv Tsev / CEP 20705 ib √ PEB 2015-240
    kev nugnthuav dav